• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

11.44 +0.59 (+5.44%)
Streaming Delayed Price Updated: 2:40 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Chair
August 31, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 19, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Host R&D Day in New York City on September 22, 2026
August 05, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix H1 2026 Results: Investor Webcast Notification
July 30, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
July 15, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FDA Alignment to Advance ProstACT Global Phase 3 Trial
July 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
June 22, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and United Imaging Announce Strategic Theranostics Collaboration
June 02, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
May 27, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
May 15, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
May 04, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX101-Px (Pixlumi®) MAA Accepted in Europe
April 30, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
April 29, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
April 27, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
April 21, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
April 14, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
April 13, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
April 13, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Accepts NDA for TLX101-Px (Pixclara®)
April 09, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Strengthens Board with Additional Director Appointments
April 08, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
April 06, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Non-Executive Director
April 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
March 15, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
March 09, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap